Genmab | GEN - Operating Profit

Stock Price
1,714.50
Daily Change
0 0%
Monthly
-6.05%
Yearly
23.43%
Q1 Forecast
1,614.31

Genmab reported DKK360M in Operating Profit for its fiscal quarter ending in June of 2025.





Operating Profit Change Date
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Almirall EUR 30.23M 12.8M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 3.96B 464M Dec/2025
argenx SE USD 371.14M 21.17M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
Bayer EUR 1.11B 1.65B Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Demant DKK 2.09B 224M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Fresenius Medical Care EUR 663M 213.06M Dec/2025
Galapagos EUR 780.56M 822.23M Dec/2025
Genmab DKK 360M 172M Jun/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
GN Store Nord DKK 570M 230M Dec/2025
GRIFOLS EUR 275.38M 76.74M Dec/2025
Hikma Pharmaceutical USD 348M 161M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Lonza CHF 430M 104M Dec/2024
Merck EUR 474M 738M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
UCB EUR 1B 678M Dec/2024